S&P gives Sharp, loans B-

S&P said it gave Sharp Midco LLC, its planned $90 million revolving credit facility and proposed $465.5 million first-lien term loan B- ratings. The recovery rating on the loans is 3, mirroring an expectation for meaningful recovery (50%-70%; rounded estimate 65%) in default. Sharp also plans to secure an unrated $157.5 million second-lien term loan.

Sharp’s owner Clayton, Dubilier, and Rice intends to spin it out from UDG Healthcare Ltd. CD&R will capitalize the company with the revolver, the two term loans and $641 million of preferred equity.

“Our ratings reflect the company's limited scale (about $380 million last-12-month revenue), narrow focus on outsourced pharmaceutical packaging, and limited negotiating power with much larger pharmaceutical customers. We also consider the potential risk of in-sourcing by large customers and the potential competition from larger, better-capitalized industry participants,” S&P said in a press release.

The outlook is stable, reflecting a forecast the company will post 8%-14% revenue growth annually over the next two years, maintain steady margins and generate modest free operating cash flow, the agency said.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.